Biolife Solutions Inc. (BLFS) is a leading developer, manufacturer and supplier of best-in-class cell and gene therapy bioproduction tools and services. Since its inception, this trailblazing company has been championing the development of innovative, proprietary solutions designed to increase the shelf life and improve the performance of biologic materials used in cell and gene therapies.
Headquartered in Bothell, Washington, Biolife Solutions has built a reputable name in the field of clinical grade biologic source material for cellular therapy applications. The uniqueness of BLFS lies in its focus on developing products that ensure optimal viability and function of biologic sources, key components that contribute significantly to the success of innovative new therapies.
BLFS's flagship product is CryoStor, a clinical grade freeze media, explicitly engineered to mitigate the cold-induced, apoptotic and necrotic damage pathways encountered by cells during the cryopreservation process. Their portfolio also includes HypoThermosol, a proprietary, optimized hypothermic storage and shipping media product, renowned for its capability in extending the shelf life of biologic source material.
One of the key strategic advances of Biolife Solutions is the acquisition of Astero Bio Corporation and SAVSU Technologies. These acquisitions have expanded BLFS's product offering to include novel thawing media and state-of-the-art cold storage and distribution products for cells, tissues, and organs.
Biolife Solutions, with its ongoing commitment towards research and development, continues its strategic collaborations with academic and industry thought leaders to bridge the gap between basic science and applied product development. These collaborations help the company to stay ahead of the curve and ensure an improved yield and extending viability of biologic source material.
In recent years, the company has significantly grown in numbers and reputation. Biolife Solutions has been supporting thousands of customers worldwide, ranging from large biopharma companies to small start-ups, and even academic research institutions, all striving to develop the next generation of cell and gene therapy breakthroughs.
In conclusion, Biolife Solutions Inc. (BLFS), with its robust line of biopreservation media products, state-of-the-art cold chain storage, and distribution solutions continues to be a critical ally for the rapidly emerging cell and gene therapy sector. The company's commitment to innovation and excellence rightly positions BLFS at the forefront of this exciting and potentially life-altering field.